Search PubMed⌕ Search

Biomedical subjects

S Vandel

Publications and source records attributed to S Vandel.

At least 73 records · Page 4Linked to original sources
PubMedDate not supplied

[Consumption of benzodiazepines in a university hospital center].

Benzodiazepine consumption has been studied in an inpatient population of a hospitalo-universitary center. The different user wards were classified by their cost or the importance of their benzodiazepine use. In a second step, the authors studied the prescription in the 6 most consumer medical wards. The most prescribed benzodiazepines were lorazepam and dipotassium clorazepate (27 and 23% respectively). In these six wards, on the day of the study, 48% of the 227 inpatients were taking benzodiazepines. Fourteen out of them were taking more than one of these drugs. In 80% of the cases, the patient was asking for the prescription. Out of the 110 inpatients found to have taken a benzodiazepine on the day of the study, 74 had already regularly used it during the years before hospital admission, mainly women (64%) and old people. Finally, out of the 227 inpatients studied, the hospitalization is a possible inducer of the benzodiazepine intake and dependence in 16% of the patients. The results are discussed against the background of other studies concerning benzodiazepine consumption.

Adult↗
PubMedDate not supplied

[The link between suicide and depression. Epidemiologic aspects].

Reviewing the literature, the authors offer a synthesis about the relations between depression and its possibly lethal outcome. The first approach of the topic is descriptive and deals with the quantification of the relations between depression and suicide. A double aspect can be distinguished. The first aspects considers depression as a cause of suicide. Using literature data, one can estimate that 60 to 70% of the subjects attempting suicide were suffering of mood disorders. Such figures are suggested by the studies offering the best methodological characteristics. The second aspect deals with the risk of suicide for depressed patients. The average annual risk is about 3/1000. Actually such a risk is mainly concentrated in the periods of active depression. Two others indices may be proposed to quantify the risk of suicide for depressed patients: the lifetime risk, which is about 15%, and the relative risk as compared with the general population not suffering from depressive disorders, which is about 30. The second approach of the topic is analytic and concerns the risk factors of suicide among depressed patients. Five groups of factors can be considered: The sociodemographic factors: depressed men are more at risk than depressed women. It is the case too for people living alone or having suffered of affective isolation during their childhood or their adolescence. Age does not seem to play a role. The nosographic factors: neither the bipolar--unipolar subtypes distinction nor the endogenous--non endogenous subtypes distinction contribute to the determination of a risk factor. Similarly, the recurrent--non recurrent subtypes distinction is not helpful.(ABSTRACT TRUNCATED AT 250 WORDS)

Bipolar Disorder↗
PubMedDate not supplied

[Yawning and sexual excitation under clomipramine. Role of serotoninergic mechanisms. Apropos of 2 cases].

We report two cases of a singular side effect induced by clomipramine, one in a man, the other in a woman (both patients were beninese). This consisted of the occurring of the association of very frequent yawning and sexual excitation (sexual excitation with vaginal lubrification for the woman and hypogastric feeling of sexual pleasure for the man). It appeared after a few days of ambulatory treatment of a depression with clomipramine 75 mg/day. Clomipramine and demethylclomipramine blood levels were respectively 85 and 95 ng/ml and 70 and 80 ng/ml for the two patients. Three similar cases had been reported in the literature with this same tricyclic antidepressant. Recently a first case has been reported with fluoxetin. On this basis, it could be suggested that serotoninergic mechanisms are involved in the development of such clinical manifestations. But it seems reasonable to consider that serotoninergic mechanism could interact with a dopaminergic one. In favour of this hypothesis is the implication of dopaminergic mechanisms in yawning in man or in the association yawning--penile erections in the rat. Some others clinical arguments are discussed.

Adult↗
PubMedDate not supplied

Debrisoquine and dextromethorphan phenotyping and antidepressant treatment.

The correlation between debrisoquine and dextromethorphan oxidation polymorphism was studied in 16 depressed in-patients. There was a close correlation between both phenotypes (r = 0.81 p less than 0.0017). During a treatment with amitriptyline during two weeks there was no significant modification of the dextromethorphan polymorphism. In the same way, the association of amitriptyline and toloxatone during two other weeks did not change this polymorphism in a significant way, even if there was a non significant shift towards higher values of the dextromethorphan metabolic ratio.

Adult↗
PubMedDate not supplied

[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide].

Valpromide is largely used in the therapy of affective disorders for its presumed thymoregulating activity. So, it is often associated with tricyclic antidepressant treatment. Previous clinical studies lead us to consider the possibility of an interaction between valpromide and tricyclic antidepressants, interaction which could result in an increase of antidepressant plasma concentrations. But no pharmacokinetic study has been realized up to now in order to clearly demonstrate such a phenomenon. The authors studied amitriptyline and nortriptyline plasma levels in two groups of ten patients receiving 125 mg amitriptyline, once a day, during 20 days. In the second group, patients also received 600 mg valpromide daily after ten days on amitriptyline. In the first group amitriptyline and nortriptyline plasma concentrations remained stable between the tenth and the twentieth day. In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.

Amitriptyline↗
PubMedDate not supplied

[Amineptin dependence. Detection of patients at risk. Report of 8 cases].

The authors relate eight cases of amineptine dependency collected between 1980 and 1988 in 7 women and 1 man treated in the CHU of Besançon (France). The pharmacodependency appeared to be limited mainly to an abuse and a psychic dependence, i.e. a compulsive need to use the drug on a periodic (two cases) or continuing (six cases) basis in order to experience its psychomotor stimulant like effect. The used dosages ranged between 1,000 and 2,500 mg per day. The daily dose was divided into little doses, every hour for example. The induction modality was progressive during weeks or months and a stable dose period was then encountered. In one patient only, we observed a progressive increase of the dose without stabilisation of the dose. The withdrawal of amineptine was obtained without problem except in 2 cases where we observed clinical manifestations of anxiety, psychomotor agitation or bulimia during one day. Four years after the beginning, amineptine dependence was still present in 2 patients. In 4 patients we obtained an interruption of the amineptine pharmacodependency for one to three years. We did not see again the two remaining patients. In two cases, the main diagnosis, according to DSM III, was a major personality disorder (borderline). In the six other cases the diagnosis was a bipolar affective disorder (including four cases with only hypomanic episodes only). In these six patients the main characteristic of their affective illness was the association with other psychiatric disorders, especially personality disorders, such as borderline personality in one case and atypical personality with uncontrolled behavior as the main feature, in the 5 other patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMedDate not supplied

[Compliance, subdosage and overdosage of antidepressive agents in the first prescription in a hospital milieu].

It is common clinical experience that depressed patients comply poorly with their treatment schedules. In a retrospective study, the authors studied the compliance with the tricyclic antidepressant treatment (TCA) in 1,023 in-patients and evaluated the frequency of the plasma levels under or above the therapeutic range, following a first prescription of TCA. To describe the adherence to the TCA regimen, the investigators have classified patients as either "compliant" or "bad compliant" on the basis of two different arbitrary dividing points: plasma levels of tertiary OR secondary amine lower than 20 ng/ml, or plasma levels of tertiary AND secondary amine lower than 20 ng/ml. The antidepressant plasma levels were measured, on steady state conditions, using a gas chromatographic method. The incidence of bad compliance ranged between about 2.5 and 10%, depending on the criteria used, the incidence of plasma levels under or above the therapeutic window ranged respectively between 26 and 54%-4 and 24%. The results from this study should encourage TCA plasma level measurements.

Antidepressive Agents↗
PubMedDate not supplied

[Dexamethasone test: suppressors and non-suppressors, what's the difference?].

In sixty-six depressed in-patients, 20 of them showed marked resistance to suppression after dexamethasone. The authors found no difference between the two subgroups of suppressors and non suppressors, when considering the following parameters: age, sex, duration of illness, number of prior episodes, family history, intensity of depression, response to antidepressant treatment, relapses, diagnoses. Furthermore the normalization of DST after a 28 day treatment did not systematically correlate with a good clinical improvement.

Amitriptyline↗